Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat

Biochemistry

Volumn 49, Issue 47, 2010, Pages 10166-10178

  Gagnon, Keith T ^a   Pendergraff, Hannah M ^a   Deleavey, Glen F ^b   Swayze, Eric E ^c   Potier, Pierre ^d   Randolph, John ^e   Roesch, Eric B ^e   Chattopadhyaya, Jyoti ^f   Damha, Masad J ^b   Bennett, C Frank ^c   Montaillier, Christophe ^d   Lemaitre, Marc ^e,g   Corey, David R ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c ISIS PHARMACEUTICALS   (United States)

^d Parc Scientifique de Luminy   (France)

^e Glen Research Corporation   (United States)

^f UPPSALA UNIVERSITY   (Sweden)

^g Girindus America Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDES; COOPERATIVE BINDING; HUNTINGTIN; HUNTINGTON'S DISEASE; IN-CELL; IN-VITRO; MUTANT HUNTINGTIN; NEURODEGENERATIVE DISEASE; PHOSPHOROTHIOATES; RIBONUCLEASE H; SELECTIVE INHIBITION;

BIOCHEMISTRY; CELL CULTURE; NUCLEIC ACIDS; OLIGONUCLEOTIDES;

GENE EXPRESSION;

ANTISENSE OLIGONUCLEOTIDE; HUNTINGTIN; MESSENGER RNA; NUCLEIC ACID; PHOSPHOROTHIOIC ACID; RIBONUCLEASE H;

ALLELE; ARTICLE; CAG REPEAT; ENZYME ACTIVITY; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; PRIORITY JOURNAL;

ALLELES; CELL LINE; GENE EXPRESSION; HUMANS; HUNTINGTON DISEASE; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; PHOSPHOROTHIOATE OLIGONUCLEOTIDES; RIBONUCLEASE H; STRUCTURE-ACTIVITY RELATIONSHIP; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 78649379362     PISSN: 00062960     EISSN: 15204995     Source Type: Journal    
DOI: 10.1021/bi101208k     Document Type: Article

References (77)

1. Orr, H. T. and Zoghbi, H. Y. (2007) Trinucleotide repeat disorders Annu. Rev. Neurosci. 30, 575-621
2. Walker, F. O. (2007) Huntington's disease Lancet 369, 218-228
3. MacDonald, M. E., Ambrose, C. M., Duyao, M. P., Myers, R. H., Lin, C., Srinidhi, L., Barnes, G., Taylor, S. A., James, M., Groot, N., and MacFarlane, H. 1993, A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes Cell 72, 971-983
4. Rubinsztein, D. C. (2003) Molecular biology of Huntington's disease (HD) and HD-like disorders., in Genetics of Movement Disorders (Pulst, S., Ed.), pp 365 - 377, California Academic Press, Millbrae CA.
5. Rubinsztein, D. C., Leggo, J., Coles, R., Almqvist, E., Biancalana, V., Cassiman, J. J., Chotai, K., Connarty, M., Crauford, D., and Curtis, A. 1996, Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats Am. J. Hum. Genet. 59, 16-22
6. McNeil, S. M., Novelletto, A., Srinidhi, J., Barnes, G., Kornbluth, I., Altherr, M. R., Wasmuth, J. J., Gusella, J. F., MacDonald, M. E., and Myers, R. H. (1997) Reduced penetrance of the Huntington's disease mutation Hum. Mol. Genet. 6, 775-779
7. Kremer, B., Goldberg, P., Andrew, S. E., Theilmann, J., Telenius, H., Zeisler, J., Squitieri, F., Lin, B., Bassett, A., Almqvist, E., Bird, T. D., and Hayden, M. R. (1994) A worldwide study of the Huntington's disease mutation. The sensitivity and specificity of measuring CAG repeats N. Engl. J. Med. 330, 1401-1406
8. Snell, R. G., MacMillan, J. C., Cheadle, J. P., Fenton, I., Lazarou, L. P., Davies, P., MacDonald, M. E., Gusella, J. F., Harper, P. S., and Shaw, D. J. (1993) Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease Nature Genet. 4, 393-397
9. Rangone, H., Humbert, S., and Saudou, F. (2004) Huntington's disease: how does huntingtin, an anti-apoptotic protein, become toxic? Pathol. Biol. 52, 338-342
10. Luo, G. R. and Le, W. D. (2010) Collective roles of molecular chaperones in protein degradation pathways associated with neurodegenerative diseases Curr. Pharm. Biotechnol. 11, 180-187
11. Ross, C. A. and Poirier, M. A. (2004) Protein aggregation and neurodegenerative disease Nature Med. 10, S10-S17
12. Hayden, M. R., Leavitt, B. R., Yasothan, U., and Kirkpatrick, P. (2009) Tetrabenazine Nature Rev. Drug Discovery 8, 17-18
13. Stewart, J. T. (1988) Treatment of Huntington's disease with clonazepam South Med. J. 81, 102
14. Grote, H. E., Bull, N. D., Howard, M. L., van Dellen, A., Blakemore, C., Bartlett, P. F., and Hannan, A. J. (2005) Cognitive disorders and neurogenesis deficits in Huntington's disease mice are rescued by fluoxetine Eur. J. Neurosci. 22, 2081-2088
15. Peng, Q., Masuda, N., Jiang, M., Li, Q., Zhao, M., Ross, C. A., and Duan, W. (2008) The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model Exp. Neurol. 210, 154-163
16. Goehler, H., Lalowski, M., Stelzl, U., Waelter, S., Stroedicke, M., Worm, U., Droege, A., Lindenberg, K. S., Knoblich, M., and Haenig, C. 2004, A protein interaction network links GIT1, an enhancer of huntingtin aggregation, to Huntington's disease Mol. Cell 15, 853-865
17. Bae, B. I., Xu, H., Igarashi, S., Fujimuro, M., Agrawal, N., Taya, Y., Hayward, S. D., Moran, T. H., Montell, C., and Ross, C. A. 2005, p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease Neuron 47, 29-41
18. DiProspero, N. A., Chen, E. Y., Charles, V., Plomann, M., Kordower, J. H., and Tagle, D. A. (2004) Early changes in Huntington's disease patient brains involve alterations in cytoskeletal and synaptic elements J. Neurocytol. 33, 517-533
19. Charrin, B. C., Saudou, F., and Humbert, S. (2005) Axonal transport failure in neurodegenerative disorders: the case of Huntington's disease Pathol. Biol. 53, 189-192
20. Bauer, P. O. and Nukina, N. (2009) The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies J. Neurochem. 110, 1737-1765
21. Gagnon, K. T. (2010) HD Therapeutics-CHDI Fifth Annual Conference, IDrugs 13, 219 - 223.
22. Nasir, J., Floresco, S. B., O'Kusky, J. R., Diewert, V. M., Richman, J. M., Zeisler, J., Borowski, A., Marth, J. D., Phillips, A. G., and Hayden, M. R. (1995) Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes Cell 81, 811-823
23. White, J. K., Auerbach, W., Duyao, M. P., Vonsattel, J. P., Gusella, J. F., Joyner, A. L., and MacDonald, M. E. (1997) Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion Nature Genet. 17, 404-410
24. Duyao, M. P., Auerbach, A. B., Ryan, A., Persichetti, F., Barnes, G. T., McNeil, S. M., Ge, P., Vonsattel, J. P., Gusella, J. F., and Joyner, A. L. 1995, Inactivation of the mouse Huntington's disease gene homolog Hdh Science 269, 407-410
25. Drouet, V., Perrin, V., Hassig, R., Dufour, N., Auregan, G., Alves, S., Bonvento, G., Brouillet, E., Luthi-Carter, R., Hantraye, P., and Déglon, N. (2009) Sustained effects of nonallele-specific Huntingtin silencing Ann. Neurol. 65, 276-285
26. Scholefield, J. and Wood, M. J. (2010) Therapeutic gene silencing strategies for polyglutamine disorders Trends Genet. 26, 29-38
27. Miller, V. M., Xia, H., Marrs, G. L., Gouvion, C. M., Lee, G., Davidson, B. L., and Paulson, H. L. (2003) Allele-specific silencing of dominant disease genes Proc. Natl. Acad. Sci. U.S.A. 100, 7195-7200
28. van Bilsen, P. H., Jaspers, L., Lombardi, M. S., Odekerken, J. C., Burright, E. N., and Kaemmerer, W. F. (2008) Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts Hum. Gene Ther. 19, 710-718
29. Rodriguez-Lebron, E. and Paulson, H. L. (2006) Allele-specific RNA interference for neurological disease Gene Ther. 13, 576-581
30. Zhang, Y., Engelman, J., and Friedlander, R. M. (2009) Allele-specific silencing of mutant Huntington's disease gene J. Neurochem. 108, 82-90
31. Pfister, E. L., Kennington, L., Straubhaar, J., Wagh, S., Liu, W., DiFiglia, M., Landwehrmeyer, B., Vonsattel, J. P., Zamore, P. D., and Aronin, N. (2009) Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients Curr. Biol. 19, 774-778
32. Lombardi, M. S., Jaspers, L., Spronkmans, C., Gellera, C., Taroni, F., Di Maria, E., Donato, S. D., and Kaemmerer, W. F. (2009) A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference Exp. Neurol. 217, 312-319
33. Hu, J., Matsui, M., Gagnon, K. T., Schwartz, J. C., Gabillet, S., Arar, K., Wu, J., Bezprozvanny, I., and Corey, D. R. (2009) Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs Nature Biotechnol. 27, 478-484
34. Hu, J., Matsui, M., and Corey, D. R. (2009) Allele-selective inhibition of mutant huntingtin by peptide nucleic acid-peptide conjugates, locked nucleic acid, and small interfering RNA Ann. N.Y. Acad. Sci. 1175, 24-31
35. Hu, J., Dodd, D. W., Hudson, R. H., and Corey, D. R. (2009) Cellular localization and allele-selective inhibition of mutant huntingtin protein by peptide nucleic acid oligomers containing the fluorescent nucleobase [bis- o -(aminoethoxy)phenyl]pyrrolocytosine Bioorg. Med. Chem. Lett. 19, 6181-6184
36. Wheeler, T. M., Sobczak, K., Lueck, J. D., Osborne, R. J., Lin, X., Dirksen, R. T., and Thornton, C. A. (2009) Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA Science 325, 336-339
37. Corey, D. R. (2007) Chemical modification: the key to clinical application of RNA interference? J. Clin. Invest. 117, 3615-3622
38. Swayze, E. E. and Bhat, B. (2008) The Medicinal Chemistry of Oligonucleotides, in Antisense Drug Technology: Principles, Strategies, and Applications (Crooke, S. T., Ed.) 2nd ed., pp 143 - 182, CRC Press, Boca Raton, FL.
39. Raal, F. J., Santos, R. D., Blom, D. J., Marais, A. D., Charng, M. J., Cromwell, W. C., Lachmann, R. H., Gaudet, D., Tan, J. L., and Chasan-Taber, S. 2010, Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial Lancet 375, 998-1006
40. Akdim, F., Visser, M. E., Tribble, D. L., Baker, B. F., Stroes, E. S., Yu, R., Flaim, J. D., Su, J., Stein, E. A., and Kastelein, J. J. (2010) Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia Am. J. Cardiol. 105, 1413-1419
41. Akdim, F., Stroes, E. S., Sijbrands, E. J., Tribble, D. L., Trip, M. D., Jukema, J. W., Flaim, J. D., Su, J., Yu, R., and Baker, B. F. 2010, Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy J. Am. Coll. Cardiol. 55, 1611-1618
42. You, Y., Moreira, B. G., Behlke, M. A., and Owczarzy, R. (2006) Design of LNA probes that improve mismatch discrimination Nucleic Acids Res. 34, e60
43. Obika, S., Nanbu, D., Hari, Y., Andoh, J., Morio, K., Doi, T., and Imanishi, T. (1998) Stability and structural features of the duplexes containing nucleoside analogues with a fixed N-type conformation, 2′- O,4′- C -methyleneribonucleosides Tetrahedron Lett. 39, 5401-5404
44. Koshkin, A. A., Singh, S. K., Nielsen, P., Rajwanshi, V. K., Kumar, R., Meldgaard, M., Olsen, C. E., and Wengel, J. (1998) LNA (Locked Nucleic Acids): Synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition Tetrahedron 54, 3607-3630
45. Braasch, D. A., Liu, Y., and Corey, D. R. (2002) Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: effect of mRNA target sequence and chimera design Nucleic Acids Res. 30, 5160-5167
46. Kaur, H., Arora, A., Wengel, J., Maiti, S., Arora, A., Wengel, J., and Maiti, S. (2006) Thermodynamic, Counterion, and Hydration Effects for the Incorporation of Locked Nucleic Acid Nucleotides into DNA Duplexes Biochemistry 45, 7347-7355
47. Morita, K., Hasegawa, C., Kaneko, M., Tsutsumi, S., Sone, J., Ishikawa, T., Imanishi, T., and Koizumi, M. (2002) 2′- O,4′- C -ethylene-bridged nucleic acids (ENA): highly nuclease-resistant and thermodynamically stable oligonucleotides for antisense drug Bioorg. Med. Chem. Lett. 12, 73-76
48. Koizumi, M., Morita, K., Daigo, M., Tsutsumu, S., Abe, K., Obika, S., and Imanishi, T. (2003) Triplex formation with 2′- O,4′- C -ethylene-bridged nucleic acids (ENA) having C 3′-endo conformation at physiological pH Nucleic Acids Res. 31, 3267-3273
49. Seth, P. P., Siwkowski, A., Allerson, C. R., Vasquez, G., Lee, S., Prakash, T. P., Wancewicz, E. V., Witchell, D., and Swayze, E. E. (2009) Short antisense oligonucleotides with novel 2′-4′ conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals J. Med. Chem. 52, 10-13
50. Prakash, T. P., Siwkowski, A., Allerson, C. R., Migawa, M. T., Lee, S., Gaus, H. J., Black, C., Seth, P. P., Swayze, E. E., and Bhat, B. (2010) Antisense oligonucleotides containing conformationally constrained 2′,4′-(N -methoxy)aminomethylene and 2′,4′- aminooxymethylene and 2′- O,4′- C -aminomethylene bridged nucleoside analogues show improved potency in animal models J. Med. Chem. 53, 1636-1650
51. Srivastava, P., Barman, J., Pathmasiri, W., Plashkevych, O., Wenska, M., and Chattopadhyaya, J. (2007) Five- and six-membered conformationally locked 2′,4′-carbocyclic ribo-thymidines: synthesis, structure, and biochemical studies J. Am. Chem. Soc. 129, 8362-8379
52. Allart, B., Khan, K., Helmut, R., Schepers, G., Hendrix, C., Rothenbacher, K., Seela, F., Van Aerschot, A., and Herdewijn, P. (1999) d -Altritol nucleic acids (ANA): hybridisation properties, stability, and initital structural analysis Chem.-Eur. J. 5, 2424-2431
53. Teplova, M., Minasov, G., Tereshko, V., Inamati, G. B., Cook, P. D., Manoharan, M., and Egli, M. (1999) Crystal structure and improved antisense properties of 2′- O -(2-methoxyethyl)-RNA Nature Struct. Biol. 6, 535-539
54. Kawasaki, A. M., Casper, M. D., Freier, S. M., Lesnik, E. A., Zounes, M. C., Cummins, L. L., Gonzalez, C., and Cook, P. D. (1993) Uniformly modified 2′-deoxy-2′-fluoro phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets J. Med. Chem. 36, 831-841
55. Watts, J. K. and Damha, M. J. (2008) 2′F-Arabinonucleic acids (2′F-ANA)-History, properties, and new frontiers Can. J. Chem. 86, 641-656
56. Damha, M. J., Wilds, C. J., Noronha, A., Brukner, I., Borkow, G., Arion, D., and Parniak, M. A. (1998) Hybrids of RNA and arabinonucleic acids (ANA and 2′F-ANA) are substrates of ribonuclease H J. Am. Chem. Soc. 120, 12976-12977
57. Bonham, M. A., Brown, S., Boyd, A. L., Brown, P. H., Bruckenstein, D. A., Hanvey, J. C., Thomson, S. A., Pipe, A., Hassman, F., and Bisi, J. E. 1995, An assessment of the antisense properties of RNase H-competent and steric-blocking oligomers Nucleic Acids Res. 23, 1197-1203
58. Broda, M., Kierzek, E., Gdaniec, Z., Kulinski, T., and Kierzek, R. (2005) Thermodynamic stability of RNA structures formed by CNG trinucleotide repeats. Implication for prediction of RNA structure Biochemistry 44, 10873-10882
59. Sobczak, K., Michlewski, G., de Mezer, M., Kierzek, E., Krol, J., Olejniczak, M., Kierzek, R., and Krzyzosiak, W. J. (2010) Structural diversity of triplet repeat RNAs J. Biol. Chem. 285, 12755-12764
60. Chakrabarti, M. C. and Schwarz, F. P. (1999) Thermal stability of PNA/DNA and DNA/DNA duplexes by differential scanning calorimetry Nucleic Acids Res. 27, 4801-4806
61. Kaur, H., Wengel, J., and Maiti, S. (2008) Thermodynamics of DNA-RNA heteroduplex formation: effects of locked nucleic acid nucleotides incorporated into the DNA strand Biochemistry 47, 1218-1227
62. Kozlowski, P., de Mezer, M., and Krzyzosiak, W. J. (2010) Trinucleotide repeats in human genome and exome Nucleic Acids Res. 38, 4027-4039
63. Omi, K., Hachiya, N. S., Tokunaga, K., and Kaneko, K. (2005) siRNA-mediated inhibition of endogenous Huntington disease gene expression induces an aberrant configuration of the ER network in vitro Biochem. Biophys. Res. Commun. 338, 1229-1235
64. Brion, P., Michel, F., Schroeder, R., and Westhof, E. (1999) Analysis of the cooperative thermal unfolding of the td intron of bacteriophage T4 Nucleic Acids Res. 27, 2494-2502
65. Mergny, J.-L. and Lacroix, L. (2003) Analysis of thermal melting curves Oligonucleotides 13, 515-537
66. Ikeda, H., Fernandez, R., Wilk, A., Barchi, J. J., Jr., Huang, X., and Marquez, V. E. (1998) The effect of two antipodal fluorine-induced sugar puckers on the conformation and stability of the Dickerson-Drew dodecamer duplex [d(CGCGAATTCGCG)]2 Nucleic Acids Res. 26, 2237-2244
67. Mangos, M. M., Min, K.-L., Viazovkina, E., Galarneau, A., Elzagheid, M. I., Parniak, M. A., and Damha, M. J. (2002) Efficient RNase H-directed cleavage of RNA promoted by antisense DNA or 2′F-ANA constructs containing acyclic nucleotide inserts J. Am. Chem. Soc. 125, 654-661
68. Kaur, H., Wengel, J., and Maiti, S. (2007) LNA-modified oligonucleotides effectively drive intramolecular-stable hairpin to intermolecular-duplex state Biochem. Biophys. Res. Commun. 352, 118-122
69. Crooke, S. T. (2004) Progress in antisense technology Annu. Rev. Med. 55, 61-95
70. Henry, S. P., Templin, M. V., Gillett, N., Rojko, J., and Levin, A. A. (1999) Correlation of Toxicity and Pharmacokinetic Properties of a Phosphorothioate Oligonucleotide Designed to Inhibit ICAM-1 Toxicol. Pathol. 27, 95-100
71. Ferdinandi, E. S., Vassilakos, A., Lee, Y., Lightfoot, J., Fitsialos, D., Wright, J. A., and Young, A. H. (2010) Preclinical toxicity and toxicokinetics of GTI-2040, a phosphorothioate oligonucleotide targeting ribonucleotide reductase R2, Cancer Chemother. Pharmacol. 66, doi: 10.1007/s00280-010-1473-z.
72. Andrew, S. E., Goldberg, Y. P., Kremer, B., Telenius, H., Theilmann, J., Adam, S., Starr, E., Squitieri, F., Lin, B., and Kalchman, M. A. 1993, The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington′s disease Nature Genet. 4, 398-403
73. Michlewski, G. and Krzyzosiak, W. J. (2004) Molecular architecture of CAG repeats in human disease related transcripts J. Mol. Biol. 340, 665-679
74. Hua, Y., Sahashi, K., Hung, G., Rigo, F., Passini, M. A., Bennett, C. F., and Krainer, A. R. (2010) Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model Genes Dev. 24, 1634-1644
75. Smith, R. A., Miller, T. M., Yamanaka, K., Monia, B. P., Condon, T. P., Hung, G., Lobsinger, C. S., Ward, C. M., McAlonis-Downes, M., and Wei, H. 2006, Antisense oligonucleotide therapy for neurodegenerative disease J. Clin. Invest. 116, 2290-2296
76. Watts, J. K., Deleavey, G. F., and Damha, M. J. (2008) Chemically modified siRNA: tools and applications Drug Discovery Today 13, 842-855
77. Dias, N., Dheur, S., Nielsen, P. E., Gryaznov, S., Van Aerschot, A., Herdewijn, P., Helene, C., and Saison-Behmoaras, T. E. (1999) Antisense PNA tridecamers targeted to the coding region of Ha-ras mRNA arrest polypeptide chain elongation J. Mol. Biol. 294, 403-416